Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
168.6 SAR | +0.96% | +4.46% | -1.86% |
09:00am | Dallah Healthcare Posts Higher Q1 Net Profit, Revenue | MT |
Mar. 20 | Dallah Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 42.64 and 31.82 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.86% | 4.35B | - | ||
-19.34% | 16.51B | B+ | ||
+5.41% | 12.53B | B | ||
+4.64% | 11.74B | B+ | ||
+2.21% | 10.06B | B+ | ||
+29.08% | 8.71B | B | ||
-3.46% | 7.57B | A- | ||
+18.60% | 7.14B | D | ||
+5.17% | 6.68B | B- | ||
+44.78% | 4.54B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4004 Stock
- Ratings Dallah Healthcare Company